Abstracts Archive - Page 1786 of 2607 - ACR Meeting Abstracts

Abstract Number: 2809 • 2016 ACR/ARHP Annual Meeting
Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories
Marc Chevrier, Jarrat Jordan, Jessica Schreiter and Jacqueline Benson, Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: Serological positivity defined by presence of anti-nuclear antibodies (ANA) is frequently used in interventional lupus trials as an inclusion criterion and longitudinal biomarker. As such,…
Abstract Number: 2810 • 2016 ACR/ARHP Annual Meeting
Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
Grant Hughes¹, Christian Lood², Uche Obih¹ and David Koelle¹, ¹University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The interferon gamma (IFN-G) release assay (IGRA) estimates probability of latent TB infection (LTBI) based on IFN-G released by whole blood after 18h exposure…
Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Ioanna Giannakou¹, Katerina Chatzidionysiou², Noémi Györi³, Laurence S Magder⁴, Ronald F. van Vollenhoven^5,6 and Michelle Petri⁷, ¹Department of Medicine, Karolinska Institute, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Unit, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…
Abstract Number: 2812 • 2016 ACR/ARHP Annual Meeting
Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans
S. Sam Lim¹, Doug McKinnell², M Edward Pierson³ and Faye O'Brien³, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Deloitte UK Life Sciences Advisory, London, United Kingdom, ³AstraZeneca, Gaithersburg, MD
Background/Purpose: Clinical trials of patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) can be confounded by difficulties in engaging patients. Identifying factors of…
Abstract Number: 2813 • 2016 ACR/ARHP Annual Meeting
Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics
Laurence S Magder¹, Erik Barr² and Michelle Petri³, ¹Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at elevated risk for lupus nephritis and ultimately renal failure. While some risk factors for renal…
Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Mônica Simon Prado¹, Alessandra Dellavance², Sílvia H. Rodrigues³ and Luis Eduardo C. Andrade^4,5, ¹Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, São Paulo, Brazil, ²Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁴Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁵Fleury Health and Medicine, Sao Paulo, Brazil
Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…
Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Juliana Valim¹, Verônica Lima², Fernanda Guimarães³, Fernanda Chaer⁴ and Branca Souza⁵, ¹Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ²Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…
Abstract Number: 2816 • 2016 ACR/ARHP Annual Meeting
Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature
Takahiro Sato, Matteo Cesaroni, Jessica Schreiter, Jarrat Jordan, Marc Chevrier and Jacqueline Benson, Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide range of clinical manifestations. Production of autoantibodies is a hallmark of SLE and…
Abstract Number: 2817 • 2016 ACR/ARHP Annual Meeting
Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers
José A. Gómez-Puerta¹, Blanca Ortiz², Tomás Urrego¹, Adriana L Vanegas³, Carlos Horacio Muñoz⁴, Mauricio Restrepo³, Wilmer Rojas-Zuleta³, Sofia Arteaga³, Luis Alonso Gonzalez⁵, Mauricio Rojas² and Gloria Vásquez^5,6, ¹Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, medellin, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellín, Colombia, ⁴Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁵Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia, ⁶Grupo de Inmunología Celular e Inmunogenética (GICIG), Universidad de Antioquia, Medellín, Colombia
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous disease, with a considerably variability of disease expression among patients. There have been several attempts to classify…
Abstract Number: 2818 • 2016 ACR/ARHP Annual Meeting
High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE
John A. Reynolds¹, Sahena Haque², Eoghan M. McCarthy³, Jamie C Sergeant⁴, Elaine Lee⁵, Eileen Holling Lee⁵, Steven Kilfeather⁵, Benjamin Parker⁶ and Ian N. Bruce⁷, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Rheumatology department, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁵Aeirtec Limited, UK, North Shields, United Kingdom, ⁶Centre for Musculoskeletal Research, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Patients with SLE have a broad clinical and immunological phenotype in which multiple immune pathways may be sequentially or simultaneously activated. No reliable biomarkers…
Abstract Number: 2819 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations
Simone Mader¹, Yoshiyuki Arinuma¹, Venkatesh Jeganathan¹, Yuichiro Fujieda², Irena Dujmovi³, Jelen Drulovic³, Yuko Sakuma⁴, Shinsuke Yasuda⁵, Joel Stern⁶, Cynthia Aranow⁶, Meggan Mackay⁷, Tatsuya Atsumi⁵, Shunsei Hirohata⁸ and Betty Diamond⁹, ¹Center of Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Clinical Centre of Serbia University School of Medicine, Belgrade, Serbia, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁶The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁸Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁹Autoimmune & Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the presence of autoantibodies. Among the complications of SLE, neuropsychiatric manifestations (NPSLE) can…
Abstract Number: 2820 • 2016 ACR/ARHP Annual Meeting
Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis
Samantha Stanley¹, Huihua Ding², Claudia Pedroza³, Ramesh Saxena⁴, Michelle Petri⁵ and Chandra Mohan¹, ¹Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering Department, University of Houston, Houston, TX, ³Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁴Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An aptamer-based screening assay was used to analyze the levels of 1129 different proteins in 24 human urine samples (8 active lupus nephritis (LN),…
Abstract Number: 2821 • 2016 ACR/ARHP Annual Meeting
Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?
Chi Chiu Mok¹, Ling Yin Ho², Chi Hung To³ and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To evaluate whether hyperuricemia is independently associated with cardiovascular events in a cross-sectional study of Chinese patients with SLE. Methods: Consecutive patients who fulfilled…
Abstract Number: 2822 • 2016 ACR/ARHP Annual Meeting
Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Chi Chiu Mok¹, Eric Bro², Ling Yin Ho³, Ravinder Singh² and Paul Jannetto⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ⁴Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic, Rochester, MN
Background/Purpose: To study the relationship between serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus (SLE) in a longitudinal cohort of Chinese patients. Methods:…
Abstract Number: 2823 • 2016 ACR/ARHP Annual Meeting
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Chi Chiu Mok¹, Samar Soliman², Ling Yin Ho³ and Chandra Mohan², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Biomedical Engineering, University of Houston, Houston, TX, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: Proteomic screening is an efficient approach for identifying protein biomarkers in various inflammatory diseases. Our preliminary proteomic analysis revealed elevated levels of urinary angiostatin,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].